Every Form 4 that Quaker Houghton (KWR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KWR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KWR filings page.
QUAKER CHEMICAL CORP (KWR) reported an insider ownership change by Gulf Hungary Holding Korlatolt Felelossegu Tarsasag, a ten percent owner. On August 20, 2026, an affiliated entity disposed of 5,017 shares of common stock at $169.29 per share in an “other” type transaction, with the shares released from escrow to the issuer to satisfy indemnification obligations related to the acquisition of Global Houghton Ltd.
After these escrow releases, the reporting person beneficially owns a total of 3,639,017 Quaker Chemical shares, including 3,905 shares held directly and 3,635,112 shares held indirectly through QH Hungary Holdings Limited. The transaction was not reported as being under a Rule 10b5-1 trading plan.
Quaker Chemical Corp executive Jeewat Bijlani, EVP, Global Specialties & Chief Growth Officer, reported an "other" disposition of 7 shares of Common Stock on August 7, 2026. Footnotes state these shares had been escrowed to secure sellers' indemnification obligations from the acquisition of Global Houghton Ltd. and were forfeited upon resolution of remaining indemnification claims and release of the escrow. The reported price of $153.20 per share is a volume-weighted average used for escrow calculations. After this event, Bijlani held 6,741 shares directly and 62 shares indirectly via a 401(k) plan, with the plan balance based on a statement as of June 30, 2026.
Quaker Chemical Corp director William H. Osborne reported a sale of 600 shares of common stock on August 4, 2026, in an open market or private transaction at $168.31 per share, leaving 616 shares held directly. He also reports 6,285 shares held indirectly through the Revocable Trust Agreement of William H. Osborne, Jr. U/A/D 12/30/2004.
Quaker Chemical EVP and CFO Thomas Coler reported routine equity compensation activity. On June 15, 2026, time-based restricted stock units and related dividend equivalent rights vested and converted into a total of 2,420 shares of common stock. In connection with this vesting, 741 shares were surrendered to cover withholding taxes, a non-market disposition that does not represent an open-market sale. The transactions reflect compensation vesting and derivative exercises rather than discretionary buying or selling.
Quaker Chemical director Lucrece Foufopoulos - De Ridder reported routine equity compensation and related tax withholding. On June 1, 2026, the director received 413 shares of common stock at $145.24 per share, reflecting 75% of the annual retainer paid in shares under the 2023 Director Stock Ownership Plan. On the same date, 124 shares were surrendered to cover statutory withholding taxes tied to these shares. After these transactions, the director directly owned 2,570 shares of Quaker Chemical common stock.
Quaker Chemical director Lucrece Foufopoulos - De Ridder reported routine equity compensation and related share movements. On June 1, 2026, she received a grant of 975 restricted stock units (RSUs) as part of 2026 compensation for non-management directors, which vest 100% on May 31, 2027 and accrue dividend equivalent rights.
On May 31, 2026, earlier time-based RSUs granted on June 1, 2025 fully vested, converting into 1,198 shares of common stock, and 18 dividend equivalent rights were settled into an equal number of shares. To cover statutory taxes on this vesting, 365 shares of common stock were surrendered, leaving her with 2,281 common shares held directly after these transactions.
Quaker Chemical Corp director Mark Douglas reported equity awards and vesting-related exercises. On June 1, 2026, he received a grant of 766 shares of common stock as full payment of the annual chairperson retainer valued at $110,000, which was fully vested at grant. He was also granted 975 restricted stock units as part of 2026 compensation for non-management directors, each representing a contingent right to one common share that vests 100% on May 31, 2027. On May 31, 2026, previously granted time-based RSUs from a 2025 award and associated dividend equivalent rights vested and were exercised, converting 1,198 RSUs and 18 dividend equivalent rights into 1,216 shares of common stock. Following these transactions, Douglas directly holds 6,278 shares of common stock and 975 restricted stock units.
Quaker Chemical director Fay West reported routine equity compensation activity. On June 1, 2026, West received a grant of 975 time-based restricted stock units as part of 2026 compensation, each representing one future share of KWR common stock, vesting 100% on May 31, 2027.
West also exercised previously granted restricted stock units and related dividend equivalent rights that vested on May 31, 2026, converting a total of 1,216 rights into common shares at no cash exercise price. In addition, 2,492 common shares are reported as held indirectly through The Douglas West Revocable Trust.
Quaker Chemical Corp director Russell Shaller reported equity compensation activity and vesting of prior awards. On June 1, 2026, he received a grant of 413 shares of common stock at $145.24 per share, reflecting 75% of his annual director retainer paid in stock. He was also granted 975 restricted stock units (RSUs) as part of his 2026 compensation, each representing a contingent right to one share of common stock and scheduled to vest 100% on May 31, 2027.
On May 31, 2026, time-based RSUs granted on June 1, 2025 vested in full, and related dividend equivalent rights were settled, resulting in a total of 1,216 common shares issued through derivative exercises. Following these transactions, Shaller directly owns 4,045 shares of common stock and holds 975 RSUs outstanding.
Quaker Chemical Corp director William H. Osborne reported routine equity compensation and vesting activity. On June 1, 2026, he received 975 restricted stock units, granted under the company’s Long-Term Performance Incentive Plan as part of 2026 compensation. Each unit represents a contingent right to one share of KWR common stock and is scheduled to vest 100% on May 31, 2027, with dividend equivalent rights accruing as dividends are paid.
Separately, time-based restricted stock units granted on June 1, 2025 vested 100% on May 31, 2026, converting into 1,198 common shares plus 18 shares from dividend equivalent rights, all at a stated price of $0.00 per share. Following these transactions, Osborne holds 1,216 common shares directly and 6,285 common shares indirectly through a revocable trust. The filing shows no open‑market buys or sales, only grants and derivative exercises.
QUAKER CHEMICAL CORP director Sanjay Hinduja reported compensation-related equity awards and vesting activity. On June 1, 2026, he received 975 restricted stock units (RSUs) as part of 2026 compensation under the Long-Term Performance Incentive Plan. These RSUs convert into common stock on a one-for-one basis and vest 100% on May 31, 2027, with dividend equivalent rights accruing as dividends are paid.
Previously granted time-based RSUs from June 1, 2025 vested in full on May 31, 2026, leading to the exercise of 1,198 RSUs and 18 dividend equivalent rights into the same number of common shares at no cash cost. Following these transactions, Hinduja directly holds 5,193 shares of common stock and 975 unvested RSUs. All reported transactions are acquisitions or conversions rather than market purchases or sales.
Quaker Chemical Corp director Charlotte C. Henry reported equity-based compensation and related exercises. On June 1, 2026 she received 975 restricted stock units under Quaker Houghton's Long-Term Performance Incentive Plan as part of her 2026 compensation. These units vest 100% on May 31, 2027 and accrue dividend equivalent rights when dividends are paid.
On May 31, 2026 she exercised 1,198 time-based restricted stock units that had vested and 18 dividend equivalent rights, converting a total of 1,216 units into common shares at no cash exercise price. Following these transactions she holds 4,487 shares of common stock directly and 975 unvested restricted stock units.
Quaker Chemical Corp director Jeffry D. Frisby reported routine equity compensation and award vesting activity. On June 1, 2026, he received a grant of 975 restricted stock units, each representing a contingent right to one share of KWR common stock, as part of 2026 compensation for non-management directors under the Long-Term Performance Incentive Plan.
On May 31, 2026, previously granted time-based restricted stock units from June 1, 2025 vested 100%. In connection with this vesting, he exercised restricted stock units and related dividend equivalent rights, converting derivative awards into a total of 1,216 shares of common stock. The dividend equivalent rights had accrued over time as cash dividends were paid on KWR common stock, with each right economically equivalent to one share.
BAKHSHI NANDITA reported acquisition or exercise transactions in this Form 4 filing.
Quaker Chemical Corp director Nandita Bakhshi received equity compensation in the form of common shares and restricted stock units. On June 1, 2026, she was granted 413 shares of common stock at $145.24 per share, representing 75% of her annual director retainer paid in stock.
She was also granted 975 restricted stock units (RSUs) as part of 2026 compensation, each representing one future share of common stock and accruing dividend equivalent rights, vesting 100% on May 31, 2027. On May 31, 2026, previously granted RSUs and related dividend equivalent rights totaling 1,216 shares of common stock vested and were settled, leaving her with 3,059 common shares held directly and 975 RSUs outstanding.
Quaker Chemical Corp EVP Jeewat Bijlani reported an option exercise and related share sale. On 2026-05-26, he exercised employee stock options for 731 shares of common stock at $136.64 per share and sold 731 shares in an open-market transaction at a weighted average price of $145.7678 per share. Following these transactions, he held 6,748 shares of common stock directly and 62 shares indirectly through a 401(k) plan.
QH Hungary Holdings Ltd, a 10% owner of Quaker Chemical Corp, reported a series of derivative transactions involving Variable Prepaid Forward Sale Contracts on May 26, 2026. These contracts reference an aggregate of 341,612 shares of Quaker Chemical common stock.
All nine entries are coded as "J" transactions, described as "other acquisition or disposition" of derivative securities and classified as restructuring events, with no open‑market buys or sells reported. The filing shows no net share purchases or sales, only structural changes in derivative positions linked to the common stock.
Gulf Hungary Holding Korlatolt Felelossegu Tarsasag, a more than 10% owner of Quaker Chemical Corp, reported nine derivative transactions involving Variable Prepaid Forward Sale Contracts tied to an aggregate of 341,612 shares of common stock. Each transaction is coded “J” as an “other acquisition or disposition” and classified as a restructuring event, with no open-market purchases or sales reported. The interests are held indirectly through QH Hungary Holdings Limited.
Meagher Kevin K. reported acquisition or exercise transactions in this Form 4 filing.
Quaker Chemical Corp VP Kevin K. Meagher reported an amended insider transaction reflecting a compensation grant of 445 Restricted Stock Units (RSUs) tied to the company’s common stock. This corrects a previously reported grant of 297 RSUs. Each RSU represents a contingent right to receive one share of KWR common stock.
The RSUs were granted under the company’s Long-Term Performance Incentive Plan and will vest in three annual installments beginning on March 15, 2027. Dividend Equivalent Rights accrue on these RSUs when and as dividends are paid on Quaker Chemical common stock.
Frodl Andre reported acquisition or exercise transactions in this Form 4 filing.
Quaker Chemical Corporation reported that VP of R&D–Metals & Metalworking Andre Frodl received a grant of 724 Restricted Stock Units (RSUs) on March 15, 2026 under the company’s Long-Term Performance Incentive Plan. An earlier Form 4 had mistakenly shown 371 RSUs. Each RSU represents one share of KWR common stock, with Dividend Equivalent Rights accruing when dividends are paid. The RSUs will vest in three annual installments beginning on March 15, 2027.
Quaker Chemical Corp senior vice president, general counsel and corporate secretary Robert T. Traub reported a series of equity compensation transactions on March 15, 2026.
He received 1,772 time-based restricted stock units and 1,028 shares of common stock earned from performance stock units granted in 2023, following certification of the company’s adjusted return on invested capital performance. Previously granted RSUs and dividend equivalent rights were also converted into common stock.
In connection with these vestings, 562 shares of common stock were surrendered at $118.45 per share to cover withholding taxes, a non‑market disposition. After these transactions, Traub directly holds 4,351 shares of common stock, and indirectly holds 1,262 shares through a 401(k) plan as of December 31, 2025.
Quaker Chemical’s SVP and Chief Human Resources Officer Kristin Rokosky reported routine equity compensation activity. On March 15, 2026, performance stock units and restricted stock units vested and were settled into 487 shares of common stock, with additional shares from dividend equivalent rights, and she also received a new grant of 1,350 time-based RSUs that vest in three annual installments beginning March 15, 2027. In connection with these vestings, she was awarded 80 shares of common stock and then on March 16, 2026 surrendered 177 shares at $118.45 per share to cover withholding taxes. Following these transactions, Rokosky directly holds 1,109 shares of Quaker Chemical common stock, while the newly granted RSUs represent additional contingent future equity.
Quaker Chemical senior vice president Miguel Moreno Hernandez reported routine equity compensation activity involving restricted stock units, performance stock units, and related dividend equivalents. On March 15, 2026, he received grants of 759 restricted stock units and 120 shares of common stock, both at no cash cost to him. Previously awarded restricted stock units, performance stock units, and dividend equivalent rights were exercised or settled into 363 shares of common stock. To cover withholding taxes on these vestings, 241 shares of common stock were surrendered at $118.45 per share. After all transactions, he directly holds 2,184 shares of Quaker Chemical common stock, with no remaining derivative awards shown in this filing. All movements reflect compensation vesting and tax withholding, not open-market buying or selling.
Meagher Kevin K. reported acquisition or exercise transactions in this Form 4 filing.
Quaker Chemical Corporation executive Kevin K. Meagher, VP, R&D - Advanced Solutions, received a grant of 297 Restricted Stock Units (RSUs) as equity-based compensation. Each RSU represents a contingent right to receive one share of KWR common stock, with dividend equivalent rights accruing as dividends are paid.
The time-based RSUs will vest in three annual installments beginning on March 15, 2027, aligning Mr. Meagher’s long-term incentives with shareholders. Following this grant, he holds 297 RSUs directly, all subject to future vesting conditions.
Quaker Chemical SVP Ma Jun reported equity compensation activity involving restricted stock units and common shares. On March 15, 2026, Ma Jun exercised derivative awards covering 239 units tied to common stock, including performance stock units and dividend equivalent rights, converting them into common shares at a price of $0.00 per share.
The filing also shows a grant of 759 time-based restricted stock units and an award of 120 shares of common stock as compensation, all held directly. After these transactions, Ma Jun directly owns 3,295 shares of Quaker Chemical common stock. Footnotes describe multi-year vesting schedules and that RSUs and related dividend equivalents convert one-for-one into common stock.
Quaker Chemical SVP and CTO Christine Procopio Johnson reported routine equity compensation activity involving restricted stock units (RSUs) and related common shares. On March 15, 2026, 304 RSUs and 2 dividend equivalent rights converted into 306 shares of common stock, reflecting the first installment vesting of a 2025 RSU grant.
To cover withholding taxes on this vesting, 111 shares were surrendered at a price of $118.45 per share, leaving 195 common shares held directly afterward. Johnson also received a new grant of 1,013 time-based RSUs that vest in three annual installments beginning on March 15, 2027, each representing a contingent right to one share of Quaker Chemical common stock with dividend equivalents accruing over time.
Quaker Chemical vice president Andre Frodl reported multiple equity compensation events on March 15, 2026. He exercised vested performance and restricted stock units and related dividend equivalent rights into 237 shares of Common Stock, and received a separate grant of 371 time-based RSUs under the Long-Term Performance Incentive Plan.
The filing also shows an additional 72 shares of Common Stock awarded, while 149 shares were surrendered to satisfy withholding taxes on the vesting of RSUs and PSUs. Following these transactions, Frodl directly holds 771 shares of Common Stock and 371 RSUs, which vest in three annual installments beginning on March 15, 2027.
Quaker Chemical vice president and Principal Accounting Officer Steven R. Dassing reported routine stock-based compensation activity. On March 15, 2026, previously granted performance and restricted stock units, plus dividend equivalent rights, were exercised into 302 shares of common stock at a stated price of $0.00 per share.
On the same date, he received new awards of 1,823 restricted stock units and 39 shares of common stock. To cover withholding taxes on these vestings, 130 shares were surrendered at $118.45 per share. After these transactions, he directly holds 368 shares of common stock.
Quaker Chemical EVP and CFO Thomas Coler reported routine equity compensation activity involving restricted stock units (RSUs) and related common shares. On March 15, 2026, RSUs and dividend equivalent rights converted into 1,578 shares of common stock, reflecting vesting of prior awards granted under the Long-Term Performance Incentive Plan.
To cover withholding taxes on this vesting, 541 common shares were surrendered back to the company, a non-market, tax-withholding disposition. After these transactions, Coler directly held 1,478 shares of common stock. He also received a new grant of 2,870 time-based RSUs, which will vest in three annual installments beginning March 15, 2027, each RSU representing a contingent right to one share of Quaker Chemical common stock with dividend equivalent rights accruing as dividends are paid.
Quaker Chemical senior vice president Renato Carvalho reported routine equity compensation activity and related tax withholding. On March 15, 2026, he acquired a total of 264 shares of Common Stock upon vesting and settlement of previously granted Restricted Stock Units (RSUs) and Dividend Equivalent Rights tied to Performance Stock Units awarded on March 15, 2023.
He also received a new grant of 844 time-based RSUs, each representing a contingent right to one share of Quaker Chemical common stock with associated dividend equivalent rights. In addition, he was granted 63 shares of Common Stock as a separate award.
To satisfy withholding tax obligations upon partial vesting of certain RSUs and PSUs under the company’s Long-Term Performance Incentive Plan, 126 shares of Common Stock were surrendered at a price of $118.45 per share. Following these transactions, Carvalho directly holds 855 shares of Common Stock, and the derivativeSummary indicates no remaining derivative positions reported in this filing.
Quaker Chemical EVP Jeewat Bijlani increased his equity stake through vesting awards and related tax withholding. On March 15, 2026, he acquired 1,568 shares of common stock through the exercise and settlement of restricted stock units and dividend equivalent rights, all at a stated price of $0.00 per share.
He also received 2,195 new time-based restricted stock units as a compensation grant and 1,297 shares of common stock, both at no cash cost to him. To cover withholding taxes on vested performance and restricted stock awards, 923 shares of common stock were surrendered at $118.45 per share. After these transactions, he directly holds 6,748 shares of common stock, plus 61 shares held indirectly through a 401(k) plan.
Quaker Chemical CEO and President Joseph A. Berquist reported multiple equity-compensation transactions dated March 15, 2026. He acquired 3,377 shares of common stock through vesting and settlement of restricted stock units, performance stock units, and dividend equivalent rights, all converting one-for-one into common shares.
Berquist also received a new grant of 11,143 time-based restricted stock units as a long-term incentive award. To cover withholding taxes on these vestings, 1,623 shares of common stock were surrendered at a value of $118.45 per share. Following these transactions, he directly holds 15,393 common shares and indirectly holds 274 shares through a 401(k) plan.
Quaker Chemical director Michael F. Barry reported stock option and related share transactions. On February 10, 2026, he exercised 8,212 employee stock options at an exercise price of $136.64 per share, receiving the same number of common shares.
On the same date, 6,876 common shares were disposed of at $176.06 per share to cover the exercise price or tax obligations, a non‑open‑market transaction coded "F." After these transactions, Barry directly owned 78,010 shares of Quaker Chemical common stock.
Quaker Chemical executive Kevin K. Meagher received an equity grant in the form of restricted stock units tied to the company’s common stock. On January 15, 2026, he was awarded 1,898 time-based restricted stock units under the company’s Long-Term Performance Incentive Plan at a grant price of $0 per unit, all held as a direct position.
The award will vest in three equal annual installments beginning on January 15, 2027, meaning additional shares of KWR common stock may be delivered each year as the units vest. Each restricted stock unit represents the right to receive one share of KWR common stock, and dividend equivalent rights accrue on these units when and as dividends are paid on KWR’s common stock.
Quaker Chemical Corp reported that an officer serving as SVP and CHRO completed equity transactions on December 15, 2025. The officer converted 327 restricted stock units into common stock and settled 5 dividend equivalent rights, each economically equivalent to one share of KWR common stock.
After these transactions and a disposition of 92 common shares at $138.99 per share, the officer directly beneficially owned 719 shares of Quaker Chemical common stock and 655 restricted stock units. The restricted stock units were part of a 982-unit special time-based grant that vests in three equal installments beginning on December 15, 2025.
Quaker Chemical Corporation senior vice president and Regional Commercial Lead-EMEA Miguel Moreno Hernandez reported routine equity award activity involving company common stock on December 15, 2025. He acquired 278 shares of common stock upon the vesting and settlement of restricted stock units and an additional 10 shares from dividend equivalent rights, both reported as option exercises or conversions (transaction code M).
To satisfy tax withholding obligations, 143 shares of common stock were disposed of at a price of $138.96 per share (transaction code F). After these transactions, he directly holds 1,942 shares of Quaker Chemical common stock. The filing explains that restricted stock units convert into common stock on a one-for-one basis and that the RSUs stemmed from a grant of 555 time-based units awarded on December 15, 2022, which vested 50% on June 15, 2024 and 50% on December 15, 2025.
Quaker Chemical Corp officer Andre Frodl, VP, R&D-Metals & Metalworking, reported equity transactions dated 12/15/2025 involving restricted stock units that converted into common stock. He acquired 172 shares of common stock upon vesting of restricted stock units and 6 shares from related dividend equivalent rights, each right being the economic equivalent of one share of KWR common stock.
On the same date, he disposed of 85 shares of common stock at $138.96 per share, and following these transactions he directly beneficially owned 611 shares of Quaker Chemical common stock. The underlying time-based restricted stock units were granted on 12/15/2022, vesting 50% on 06/15/2024 and 50% on 12/15/2025.
Quaker Chemical Corp. director reports complex equity transactions. A Form 4 filing for Quaker Chemical Corp. (KWR) discloses that a director entered into equity-linked transactions on 11/25/2025. The director disposed of 45,000 shares of common stock in one transaction and 30,000 shares in a second transaction, both coded J/K, and continued to hold 3,635,112 shares directly afterward.
The filing also reports four variable prepaid forward sale contracts referencing Quaker Chemical common stock. These derivative positions each relate to 192,200, 128,133, 13,900, and 9,267 underlying shares, respectively, and are shown as directly owned derivative securities. Additional details and mechanics of these contracts are described in Exhibit 99.1, which contains the explanation of responses.
Quaker Chemical Corp (KWR) disclosed insider transactions by a reporting person serving as a director and 10% owner. The form shows that on 11/25/2025, the reporting person, through QH Hungary Holdings Limited, disposed of 45,000 shares of common stock in one transaction and 30,000 shares in another. After these sales, the reporting person indirectly beneficially owned 3,665,112 and then 3,635,112 shares of common stock through QH Hungary Holdings Limited.
The reporting person also entered into several variable prepaid forward sale contracts referencing Quaker Chemical common stock on the same date. These derivative positions cover 192,200, 128,133, 13,900, and 9,267 shares of common stock, respectively, all held indirectly through QH Hungary Holdings Limited. Further details and key terms are referenced in Exhibit 99.1, which provides the notes and explanations for the coded transactions.
Quaker Chemical (KWR) reported an insider equity award. The company’s SVP, CTO filed a Form 4 for the grant of 913 time‑based restricted stock units on 10/15/2025 under the Long‑Term Performance Incentive Plan.
The RSUs vest in three annual installments beginning on March 15, 2026. Each RSU represents a right to receive one share of KWR common stock, and dividend equivalent rights accrue when and as dividends are paid. Following the transaction, 913 derivative securities were beneficially owned, held directly.
Quaker Chemical (KWR) reported an insider equity grant. Officer Andre Frodl (VP, R&D–Metals & Metalworking) acquired 61 restricted stock units on 10/15/2025 under the Company’s Long-Term Performance Incentive Plan at a price of $0 per unit.
Each RSU represents the right to receive one share of KWR common stock. The RSUs vest in three annual installments beginning on March 15, 2026, and dividend equivalent rights accrue when and as dividends are paid. The holdings are reported as Direct (D) ownership.